New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients
August 18 2020 - 6:32AM
Business Wire
Niagen® (patented nicotinamide riboside) may reduce production
of inflammatory cytokines in pilot study of Stage D heart failure
patients
ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published
human trial on its patented NAD-boosting nutrient Niagen®, further
highlighting its potential to support cardiovascular health in
humans. A NIH funded study by Cardiology Division and Mitochondria
& Metabolism Center at the University of Washington, published
in The Journal of Clinical Investigation, found that Niagen
supplementation reduced signs of inflammation, specifically
inflammatory cytokines in vivo, in a small group of end-stage heart
failure patients. A second arm of the study, conducted ex vivo,
found improved mitochondrial respiration and reduced inflammatory
factor expressions in peripheral blood mononuclear cells (PBMCs)
isolated from human subjects and treated with nicotinamide
riboside.
“We found that increasing NAD levels with nicotinamide riboside
suppressed inflammatory activation in end-stage heart failure
patients,” says study co-first author Dennis Ding-Hwa Wang, M.D.,
Ph.D. “By increasing the mitochondrial health of PBMCs,
proinflammatory cytokine production was reduced. These findings
further support an important role NR may have in a variety of
cardiovascular-related health declines.”
In this most recent study, conducted through the ChromaDex
External Research Program (CERP™), patients with the most
significant forms of heart failure (Stage D) were supplemented with
NR to evaluate for improvements in inflammation. Their blood was
analyzed for levels of pro-inflammatory signaling molecules,
including IL-6, as well as the respiration rate of PBMCs in both in
vivo and ex vivo models. PBMCs have been implicated in the
inflammatory response that leads to the decompensation and
worsening of heart failure. Mitochondrial health of PBMCs, as
evidenced by the respiration rate, could be the culprit and
reporter of the inflammatory process.
The pilot study found that both the respiratory rate of PBMCs,
as well as levels of pro-inflammatory cytokine gene expressions,
were all improved following daily NR supplementation for 5-9 days.
In particular, expression of the NLRP3 inflammasome and cytokine
IL-6 were reduced in these patients following NR
supplementation.
“These new findings build upon a growing body of evidence
identifying how Niagen may support cardiovascular health,” says Dr.
Andrew Shao, ChromaDex Senior Vice President of Global Scientific
& Regulatory Affairs. “We look forward to seeing the results
from additional ongoing clinical research to further our
understanding of Niagen’s impact on cardiovascular health.”
A previous trial on ChromaDex’s nicotinamide riboside (NR, or
Niagen) published in Nature Communications in 2018 found that it
reduced systolic blood pressure in pre-hypertensive patients
relative to a placebo. While NR seems to have diverse benefits on
cardiovascular health, further research is required to establish
whether NR could play a role in preventing or slowing the
progression of heart disease.
ChromaDex, the exclusive licensee of Dr. Charles Brenner’s
patented NR, has since invested over $35 million in investigating,
manufacturing and offering NR in the form of Niagen and has secured
more than 20 patents. ChromaDex has demonstrated the safety and
efficacy of Niagen in eleven published human trials (and over 20
additional ongoing studies further evaluating its safety and
efficacy) and has achieved government regulatory acceptance in the
United States, Canada, the European Union, and Australia.
For additional information on ChromaDex, visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical
company devoted to improving the way people age. ChromaDex
scientists partner with leading universities and research
institutions worldwide to discover, develop and create solutions to
deliver the full potential of NAD and its impact on human health.
Its flagship ingredient, NIAGEN® nicotinamide riboside, sold
directly to consumers as TRU NIAGEN®, is backed with clinical and
scientific research, as well as extensive IP protection. TRU
NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a
website at www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether Niagen may support
cardiovascular health in humans or prevent or slow the progression
of heart disease. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2019 as amended, ChromaDex's
Quarterly Reports on Form 10-Q and other filings submitted by
ChromaDex to the SEC, copies of which may be obtained from the
SEC's website at www.sec.gov. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200818005196/en/
ChromaDex Media Contact: Alex Worsham, Senior Director of
Global Corporate Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024